A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R.sup.1, R.sup.3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R.sup.3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.

##STR00001##

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

The invention relates to a hybrid proteinaceous molecule comprising at least two proteins capable of inhibiting the activity of at least one antibiotic, the proteins each having different biochemical properties and being bonded to one another. The hybrid proteinaceous molecule inhibits the activity of a least one antibiotic in order to reduce the intestinal side effects of antibiotics, such as severe diarrhoea caused by the antibiotics, and nosocomial infections secondary to parenteral antibiotic therapy.

The present disclosure provides methods, reagents, systems, and devices that target β lactamase as a biomarker for the sensitive and specific detection of tuberculosis-complex bacteria. Specifically, the present disclosure relates to methods and compositions for the detection of specific β-lactamase protein and nucleic acid sequences to indicate the presence of tuberculosis-complex bacteria.

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.

The present invention provides a universal delivery platform of functional, heterologous compounds to specific cells using toxins modified to include a heterologous compound. In one embodiment, the toxin is an AB5 toxin. In one embodiment, the AB5 toxin is a heat-labile enterotoxin from E. coli (LT), including LTI, LTII, LTIIa, LTIIb, LTIIc and other recombinant forms of LT. Methods of use are also provided.

In one embodiment, a hydrogel-enzyme construct for performing high temperature enzymatic reaction on paraoxon, and/or for performing enzymatic reaction on paraoxon following exposure to high temperature, includes a hydrogel having multiple layers of poly(methacrylic acid) (PMAA) and a plurality of dPTE2 enzyme molecules. Individual dPTE2 enzyme molecules are embedded between adjacent PMAA layers and are covalently bonded with respective individual PMAA layers. The hydrogel-enzyme construct is capable of performing enzymatic reaction on the paraoxon when the paraoxon is exposed to the hydrogel-enzyme construct under a temperature condition of up to above 99° C. and below 100° C. or when the paraoxon is exposed to the hydrogel-enzyme construct after the hydrogel-enzyme construct has been heated to a temperature condition of up to 550° C., where the enzymatic reaction on the paraoxon by individual dPTE2 molecules embedded within the hydrogel occurs at a residual activity of between 20% and 100%.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).